ChemoCentryx's stock jumps 80% after receiving FDA approval for vasculitis drug

Published: Oct. 8, 2021 astatine 8:24 a.m. ET

Shares of ChemoCentryx Inc. CCXI, +5.43% soared 80.3% successful premarket trading connected Friday aft the institution said that it had received support from the Food and Drug Administration for its ANCA-associated vasculitis therapy. The institution said this is the archetypal caller cause to dainty the uncommon autoimmune illness successful a decade. ChemoCentryx's banal slipped 68.3% this year, portion the broader S&P 500 SPX, +0.83% is up 16.1%.

Read Next

Read Next

Tesla moving HQ to Austin, Texas, from California, Musk tells investors

Tesla Inc. is officially moving its office to the Austin, Texas, area, Chief Executive Elon Musk told investors connected Thursday.

More On MarketWatch

• Barron's: Cathie Wood’s ARK Invest Is Leaving NYC For Florida. She’s Not The First.
• DoorDash, Uber Eats, Grubhub indispensable disclose hidden fees, springiness transportation workers each tips nether caller California law
• Barron's: Biden Administration Wants IRS to Monitor People’s Bank Accounts More Closely. Will It Catch Tax Cheats, oregon Invade Privacy?
• Walmart, Target, Home Depot and different ample retailers are chartering ships to bypass proviso concatenation problems. Will the strategy prevention Christmas?

Advertisement